Business
Is Moderna stock a hold?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
A recent downgrade from buy to hold from a Wall Street analyst has Moderna (NASDAQ: MRNA) stock under pressure. Needham analyst Alan Carr has removed his $110 price target on the stock, citing valuation concerns.
Moderna’s market cap has swelled 885% this year to around $67 billion at recent prices. Despite coming under pressure recently, this is still one of the best performing large-cap healthcare stocks of 2020.
Following a meeting on 17 December with the Food and Drug Administration’s independent advisory committee, Moderna’s coronavirus vaccine candidate MRNA-1273 will probably become the second vaccine to earn an…
-
Noosa News9 hours agoWoman dead and man rushed to hospital with gunshot wound following crash near Aussie World on Queensland’s Sunshine Coast
-
General15 hours agoBoy dies after being trapped between rocks off NSW beach
-
Noosa News16 hours agoFarmer Fred Perry’s 30-year conservation project creates bird haven after years of ‘bashing and burning’
-
Noosa News15 hours agoDetectives continue to search for answers on Crystal Beale’s death